Serplulimab is a monoclonal antibody used for the treatment of cancers.[1][2]
| Clinical data | |
|---|---|
| Other names | HLX10, HANSIZHUANG, Zerpidio |
| Routes of administration | Intravenous |
| Drug class | Antineoplastic agent |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Society and culture
editLegal status
editIt was approved for medical use in China in 2022, for the treatment of microsatellite instability-high solid tumors[2] and squamous non-small cell lung cancer,[3] and in 2023 for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and esophageal squamous cell carcinoma.[4]
In December 2023, the Indonesian Food and Drug Authority approved serplulimab for medical use in Indonesia. [5]
In September 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hetronifly, intended for the treatment of extensive-stage small cell lung cancer (ES-SCLC).[1] The applicant for this medicinal product is Henlius Europe GmbH.[1]
Names
editSerplulimab is the International nonproprietary name.[6]
References
edit- ^ a b c "Hetronifly EPAR". European Medicines Agency (EMA). 19 September 2024. Retrieved 21 September 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b Lee A (July 2022). "Serplulimab: First Approval". Drugs. 82 (10): 1137–1141. doi:10.1007/s40265-022-01740-0. PMID 35796953.
- ^ Henlius. "Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC". www.prnewswire.com. Retrieved 14 November 2024.
- ^ "Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC-Media". Henlius (Press release). 22 September 2023. Retrieved 21 September 2024.
- ^ "Kalbe Luncurkan Serplulimab Untuk Obati Kanker Paru Sel Kecil - WartaTransparansi". www.wartatransparansi.com (in Indonesian). 10 March 2024. Retrieved 14 November 2024.
- ^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
Further reading
edit- Qin S, Li J, Zhong H, Jin C, Chen L, Yuan X, et al. (December 2022). "Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial". British Journal of Cancer. 127 (12): 2241–2248. doi:10.1038/s41416-022-02001-3. PMC 9726893. PMID 36261583.
- Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. "Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial". JAMA. 328 (12): 1223–1232. doi:10.1001/jama.2022.16464. PMC 9516323.
- Wang ZX, Peng J, Liang X, Cheng Y, Deng Y, Chen K, et al. (September 2024). "First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial". Med (New York, N.Y.). 5 (9): 1150–1163.e3. doi:10.1016/j.medj.2024.05.009. PMID 38870931.
- Xiang G, Jiang T, Gan L, Wu Y, Zhang N, Xing H, et al. (2023). "Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China". Frontiers in Immunology. 14: 1223020. doi:10.3389/fimmu.2023.1223020. PMC 10501445. PMID 37720211.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |